Paris, January 7th, 2020 – PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH, the German medical product and well-being company. PKvitality is currently working on the development of K’Watch project, a Continuous Glucose Monitor (CGM) in a form of a smartwatch.

The agreement provides PKvitality with €2,25m funding to further develop the K’Watch and reach First in Man. Beurer GmBH has acquired exclusive commercialisation rights for Germany, Austria and Italian tenders, agreeing to a sales volume that will contribute significantly to PKvitality’s overall commercial volume.

Beurer GmbH, created in 1919, employs more than 900 staff and manufactures and commercialises more than 500 products in Europe, US and Asia, and is one of the major distributors of Blood Glucose Meters in Germany and Austria. Beurer believes that PKvitality’s K’Watch, will become a leading product to measure blood glucoselevel in real time. The patient-friendly and cost-effective concept of the K’Watch is being developed by high skilled professionals and industry experts; Luc Pierart, CEO, ex-Alcatel Lucent and ex-Motorola, Minh Lê, General Manager, ex-Withings and Tom Bishop, CTO, 35 years’ experience in the MedTech industry, including CGM focus.

Luc Pierart, CEO and Founder of PKvitality says: “We are very proud that our technology has been endorsed by Beurer, as the depth of their due diligence and their competencies in health-care technologies are Best in Class. We trust Beurer to be the right partner for us. Their commercial footprint will provide a powerful springboard to promote our unique product, in the large and dynamic market of CGM (Continuous Glucose Monitoring). Beurer’s investment in PKvitality will also enable us to continue our development efforts and to confirm the excellent results currently obtained in our pre-clinical model, and to reach the First in Man milestone”

Luc Pierart, CEO and Founder of PKvitality says: “We are very proud that our technology has been endorsed by Beurer, as the depth of their due diligence and their competencies in health-care technologies are Best in Class. We trust Beurer to be the right partner for us. Their commercial footprint will provide a powerful springboard to promote our unique product, in the large and dynamic market of CGM (Continuous Glucose Monitoring). Beurer’s investment in PKvitality will also enable us to continue our development efforts and to confirm the excellent results currently obtained in our pre-clinical model, and to reach the First in Man milestone”

About K’Watch

K’Watch will be the first wearable smartwatch medical device that measures and displays glucose level continuously, effortlessly and painlessly. With K’Watch, diabetes patients will check their glucose level instantly, see the trend and how it evolves over a period of time. Patients will also receive customized automated alerts to prevent hyper & hypoglycaemia episodes for days and nights. Moreover, users have the option of alerting trusted people in case of severe episodes through notifications sent via the PK Application directly on their smartphone. K’Watch Glucose is equipped with K’apsul, a consumable which is inserted at its back. The core of K’apsul’s concept is the technology SkinTaste, a revolutionary technology based on a sensor composed of biochemicals and an array of micro-points. The micro-points stay in the upper part of the skin, a layer without pain sensation as most of the mechanical nerves are below 1mm. It measures glucose concentration by being in contact with the interstitial fluid rather than with the blood which makes it also a blood-free solution.

About PKvitality

PKvitality is an advanced bio-wearable start-up currently working on K’Watch, a painless and discreet Continuous Glucose Monitoring (CGM) device in the form of a smartwatch. It will enable a precise and continuous monitoring of systemic glucose level anytime and anywhere. Using the same technology, PKvitality is also working on K’Watch Athlete, a smartwatch that will provide real-time monitoring of their lactic acid – an indicator of muscle fatigue – to significantly improve an athlete’s training and performance.

PKvitality is currently finalising its Series A funding round. Interested investors can meet PKvitality at the Biotech and Medtech showcase, a satellite event to JP Morgan Healthcare Conference, from 13th to 15th January 2020 in San Francisco, California, or send enquiries to partnership@pkvitality.com.

Contacts:
Acticor Biotech:
Gilles Avenard
Chief Executive Officer
gilles.avenard@acticor-biotech.com

Media – NewCap:
Annie-Florence Loyer
afloyer@newcap.fr
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59

PKvitality Contacts
Press: press@pkvitality.com
Media content: Click here
Investors:partnership@pkvitality.com
For more information, visit https://www.pkvitality.com/